Thanks for the clinicaltrials.gov link. Artisan Pharma’s DIC program is to be taken seriously, but the existence of the program is old news (#msg-14524596).
ART-123, the product candidate Artisan is developing for DIC, is not antithrombin; rather, it is thrombomodulin, which is a fragment of the AT molecule. ART-123 is thus a new chemical entity that cannot be assumed to have the same safety and efficacy as AT.
GTC and Leo Pharma obviously considered the potential competition from ART-123 when they decided to pursue DIC as the lead acquired deficiency indication for ATryn. The sheer size of the unmet medical need presumably offset the risk that another drug might turn out to be better suited for the indication. Regards, Dew
Market Data 
Markets 
AI
